CVSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Covista Inc (CVSA) is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has a constructive technical setup, a favorable analyst initiation with upside to $130, and strong event-driven fundamentals from enrollment growth, revenue growth, higher guidance, and debt refinancing. While quarterly profit and EPS declined, the top-line outlook and strategic positioning remain positive. Given the investor is impatient and does not want to wait for a perfect entry, this is a reasonable buy now.
Current price is 118.88, slightly above the pivot at 113.046 and near resistance R1 at 118.293, showing the stock has already broken into a stronger short-term range. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports an uptrend. RSI_6 at 58.847 is neutral to mildly bullish, so the stock is not overbought. MACD histogram is -0.0952 and still below zero, but the negative momentum is contracting, which suggests weakening downside pressure. Overall, the technical picture is bullish with some near-term resistance around 118.29 to 121.53, but the trend remains favorable.
Management also raised fiscal year 2026 revenue guidance to $1.93 billion-$1.945 billion, implying 8%-9% growth. Truist initiated coverage with a Buy rating and a $130 target, citing labor shortages, upskilling demand, and insulation from AI disruption. No recent congress trading data and no notable politician/influencer buying or selling was provided.
The latest quarter showed weaker profitability: net income fell 31.55% year over year, EPS declined 24.53%, and gross margin slipped slightly to 56.73%. MACD remains negative, so momentum is not fully confirmed yet. Hedge fund and insider activity are neutral, meaning there is no strong ownership signal from those groups. The stock also sits near short-term resistance, which may cap immediate upside.
In Q3 2026, revenue increased 4.5% year over year to $487.0 million, which is a healthy growth signal. Enrollment also grew 6.8% year over year, supporting future demand. However, net income dropped 31.55% to $41.64 million and EPS fell 24.53% to $1.20, while gross margin edged down to 56.73%. The latest quarter season is Q3 2026. Overall, the business is growing on the top line, but profitability softened in the quarter.
Analyst sentiment has turned positive with Truist initiating coverage on 2026-03-24 at Buy and a $130 price target, implying upside from current levels around 118.88. The rationale is favorable: clinical healthcare-focused institutions benefit from labor shortages and upskilling trends, and the mix is seen as relatively insulated from AI disruption. Wall Street’s pros view is improving growth visibility, durable demand, and supportive catalysts. The cons view is that earnings quality weakened in the latest quarter and the stock is already somewhat extended near resistance, but the analyst trend is still constructive.
